What is the appropriate dosing schedule for transdermal estradiol patch and oral micronized progesterone in menopausal hormone therapy for a woman with an intact uterus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Hormone Therapy Dosing for Women with Intact Uterus

For menopausal hormone therapy in women with an intact uterus, use transdermal estradiol patches 50-100 μg daily continuously, combined with oral micronized progesterone 200 mg daily for 12-14 days per month (sequential regimen) or 100 mg daily continuously (continuous regimen). 1, 2

Estradiol Patch Dosing

Starting dose: 50 μg/24 hours transdermal patch, changed twice weekly or weekly depending on brand 3

Dose range: 50-100 μg/24 hours, adjusted based on symptom control and tolerability 3, 4

Why transdermal is preferred: Transdermal estradiol avoids the hepatic first-pass effect, which theoretically reduces risks of venous thromboembolism, increases in inflammatory markers (C-reactive protein), and adverse effects on triglycerides and coagulation factors compared to oral estrogen 1, 4. This makes transdermal the preferred route for women with VTE risk, hypertension, hypertriglyceridemia, obesity, metabolic syndrome, diabetes, or gallbladder disease history 4.

Micronized Progesterone Dosing (Critical for Endometrial Protection)

You must add progestogen in women with an intact uterus - unopposed estrogen increases endometrial cancer risk 1. Micronized progesterone is the preferred progestogen due to lower cardiovascular and VTE risks compared to synthetic progestins 3.

Sequential Regimen (Induces Monthly Bleeding)

  • 200 mg oral micronized progesterone daily for 12-14 days every 28 days 3, 2
  • Take at bedtime (reduces dizziness/drowsiness side effects) 2
  • This provides endometrial protection for up to 5 years 5
  • Preferred for recently menopausal women prone to breakthrough bleeding 4

Continuous Combined Regimen (Aims for Amenorrhea)

  • 100 mg oral micronized progesterone daily continuously 6, 7
  • Induces amenorrhea in 80-93% of women by 3-6 months 6, 7
  • Better compliance due to avoidance of withdrawal bleeding 6
  • Note: Some guidelines express concern about continuous progestogen exposure and breast cancer risk, though this is less established with micronized progesterone versus synthetic progestins 1

Alternative Dosing Options

  • Vaginal micronized progesterone: 100 mg every other day or 45 mg daily (4% gel) for 10+ days/month provides endometrial protection (off-label) 5, 8
  • Better bleeding control and compliance than oral in some studies 8
  • Long-cycle therapy: 200 mg for 14 days every 3 months may reduce progestogen breast exposure, though efficacy less established 1

Practical Administration Details

Timing: Take progesterone at bedtime with water while standing 2

Common side effects to counsel about:

  • Dizziness, drowsiness (especially first few weeks) 2
  • Headaches, breast tenderness 2
  • Irregular bleeding initially (improves over time) 2

Monitoring requirements:

  • Annual pelvic exam, breast exam, mammogram 2
  • Investigate any unusual vaginal bleeding 2
  • Reassess need for therapy regularly 2

Critical Contraindications

Do not use if patient has: 2

  • Peanut allergy (progesterone capsules contain peanut oil)
  • Current or history of breast cancer or estrogen-dependent cancers
  • Active or recent VTE/stroke/MI
  • Unexplained vaginal bleeding
  • Active liver disease
  • Pregnancy

Duration of Therapy

Use lowest effective dose for shortest duration necessary 1. For natural menopause, reassess annually. For premature ovarian insufficiency, continue until age 45-55 years (average natural menopause age) 3.

Key Clinical Pitfalls

  • Never give unopposed estrogen to women with intact uterus - this is Grade A contraindicated due to endometrial cancer risk 1
  • Minimum 10-14 days progesterone monthly required for adequate endometrial protection in sequential regimens 1
  • Transdermal progesterone does NOT provide endometrial protection - only oral or vaginal routes are effective 5
  • Patients may experience significant drowsiness with progesterone - always advise bedtime dosing 2

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.